SPRINT — Sprint Bioscience AB Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapNeutral

Annual income statement for Sprint Bioscience AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	33.5	16.9	35.1	0.083	50.5
Cost of Revenue
Gross Profit	25.4	6.43	24.7	-12.8	41.8
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	53.8	54.7	60.7	60.8	51.3
Operating Profit	-20.2	-37.8	-25.6	-60.7	-0.845
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-21.5	-42.8	-25.1	-60.2	-0.438
Provision for Income Taxes
Net Income After Taxes	-21.5	-42.8	-25.1	-60.2	-0.438
Net Income Before Extraordinary Items
Net Income	-21.5	-42.8	-25.1	-60.2	-0.438
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-21.5	-42.8	-25.1	-60.2	-0.438
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-1.43	-2.07	-0.724	-1.43	-0.006
Dividends per Share